Tweets
7pm ET on 11/13, join our SLE panel. #ACR22
https://t.co/B8XdaJFLS2 https://t.co/kqJRI2QRms
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 8 months ago
It's brilliant lab work @MayoClinic that had led the way for JAKi in GCA in clinical trials.
A compelling bench-to-bedside story by @MdWarrington, Dr. Weyand, Dr. Koster and team, and definitely a space to watch
#ACR22 @RheumNow https://t.co/2acKFrWOUF
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
"You won't find IgG4-RD anywhere [in the 2012 Chapel Hill nomenclature], but it is absolutely a vasculitis"
-John Stone
#ACR22 @RheumNow
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
LILAC study abstracts 0364 and 0365 SLE pts w/ joint and skin activity treated with BIIB059 had consistent improvements vs PBO. More to come! #ACR22 @RheumNow https://t.co/WPl3tol7v9 and https://t.co/8cyrI3W9rD https://t.co/5W4KMOHHEA
Links:
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Need to know! Wigley says ‘each organ system has unique properties’ so ex Rx of skin may not help vasculopathy or #SSc renal crisis Rx is ACEi vs CCB in #Raynauds. 1 drug won’t be sufficient in complex diseases #13S114 #ACR22 #ACRBest @RheumNow #ClinicalPearl https://t.co/S8fHi7dFoD
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
MoA qu in GCA:
Is one JAKi better?
lab in tofa
proof-of-concept in bari
clinical trial in upa
@MdWarrington: unclear if any diff clinically
GM-CSF vs IL-17?
Maria Cid: lots of redundancy in immune system
blocking one pathway, escalation of another?
we will see
#ACR22 @RheumNow
David Liew @drdavidliew ( View Tweet )
3 years 8 months ago
Combined pulmonary HTN and ILD seen in 7% in large scleroderma database. Unsurprisingly, survival worse then PAH/ILD alone. HAQ also worse in this group.
@RheumNow @earlyARA #ACR22 ABST1058
https://t.co/Jr58wVLC31 https://t.co/UCjKuJB1ev
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Abs 0359 TULIP-1&2 data showed nearly 10% of anifrolumab-treated pts achieved remission, suggesting that DORIS response is attainable. #ACR22 @RheumNow https://t.co/laPwd0KpSa https://t.co/6LZ1WLrc97
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 8 months ago
Great scientific talk by John Stone, IgG4-RD should be a considered a variable-vessel disease, much like Behcet's and Cogan's syndrome
I had not viewed it from that perspective; adding it to the list! Series of patietns w/coronary involvement esp interesting
#ACR22 @RheumNow https://t.co/JUayLOTnSB
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
Slow pruning of Pulmonary arteries occurs way before we detect #PAH pulmonary hypertension in #scleroderma #SSc 13S114 lecture by Fred Wigley. Screen but need data re earlier Rx before Dx of PAH. May be assoc w anticentrome and +++ telangiectasia @RheumNow #ACR22 https://t.co/AgnIMYFKjB
Janet Pope @Janetbirdope ( View Tweet )
3 years 8 months ago
#ACR22 Abstr#1464 Press Release #lupus. Should we worry of pts without nephritis & low grade proteinuria UPCR >0.2 & <0.5? A cohort study showed 50% progressed to =>0.5 at 2 yrs & 11% renal biopsy +ve. Important to monitor UPCR. Need biomarkers for this At-Risk @RheumNow #ACRBest https://t.co/eOODUynvP4
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
PCP docs managing AS?
Abstract #0078
🧑⚕️ Assessed differences in management between PCP and rheumatologists
💉RHU prescribed more biologics
💊PCP prescribed more opiate and non-opiate pain medications
💊PCP did not often prescribe csDMARDs or biologics
#ACR22 @RheumNow
Catherine Sims, MD @DrCassySims ( View Tweet )
3 years 8 months ago
